Skip to main content

From bedside to battlefield: intersection of ketone body mechanisms in geroscience with military resilience

Abstract

Ketone bodies are endogenous metabolites that are linked to multiple mechanisms of aging and resilience. They are produced by the body when glucose availability is low, including during fasting and dietary carbohydrate restriction, but also can be consumed as exogenous ketone compounds. Along with supplying energy to peripheral tissues such as brain, heart, and skeletal muscle, they increasingly are understood to have drug-like protein binding activities that regulate inflammation, epigenetics, and other cellular processes. While these energy and signaling mechanisms of ketone bodies are currently being studied in a variety of aging-related diseases such as Alzheimer’s disease and type 2 diabetes mellitus, they may also be relevant to military service members undergoing stressors that mimic or accelerate aging pathways, particularly traumatic brain injury and muscle rehabilitation and recovery. Here we summarize the biology of ketone bodies relevant to resilience and rehabilitation, strategies for translational use of ketone bodies, and current clinical investigations in this area.

Endogenous ketone production and metabolism

Ketone bodies are endogenous metabolites that have been implicated in modulation of multiple pathways relevant to aging and aging-related resilience [1]. A growing catalog of direct molecular actions support their roles in geroprotective pathways, as does circumstantial evidence from their induction in aging-relevant physiological settings such as fasting, dietary restriction, and exercise [2,3,4]. The increased physical and emotional stress experienced by military service members during their career may act to accelerate the aging process in these individuals [5, 6]. Furthermore, the military population has an increased risk of sustaining injuries and accumulating complex co-morbidities that could go on to contribute to physical disability or cognitive decline [7,8,9,10]. Therefore, there may be significant areas of application for geroscience interventions to promote resilience, improve rehabilitation, and prevent accelerated aging in active duty military and veterans alike.

Ketone bodies are small molecules synthesized primarily in the liver from fats during fasting, caloric restriction, prolonged exercise, or other circumstances when carbohydrates are scarce [2]. They circulate through the bloodstream, are transported across the blood-brain barrier, and are taken up by peripheral tissues in need of energy. They are oxidized in mitochondria to generate acetyl-CoA and thus drive the regeneration of ATP [11]. The two primary endogenous ketone bodies are acetoacetate (AcAc) and beta-hydroxybutyrate (BHB), which are interconverted in the final step in ketogenesis in the liver and the first step in ketolysis in peripheral tissues. Liver ketogenesis naturally occurs at a low level even after consumption of carbohydrate-rich meals, with AcAc and BHB found in the blood in roughly similar levels (~ 50–100 micromolar each) [12]. When ketogenesis is activated, overall ketone body levels increase into the millimolar range with a preferential increase in BHB [13]. Some of AcAc will spontaneously degrade into acetone, which is considered the third ketone body and provides the “fruity” breath scent common in diabetic ketoacidosis.

Ketone bodies have a uniquely wide physiological range that spans 3 orders of magnitude in blood concentration from as low as 0.01 mM in the carbohydrate-fed state to greater than 10 mM in diabetic ketoacidosis. Ketoacidosis is a life-threatening condition where metabolic control mechanisms such as insulin are absent or dysfunctional, and bicarbonate buffering capacity is outpaced by acid production [14]. Physiological or nutritional ketosis, such as occurs in fasting or on a ketogenic diet, lies in between these extremes of ketone levels. Physiological ketosis is an evolutionary-conserved state enabling inter-organ fuel requirements to be met without exogenous carbohydrate. In individuals with sufficient insulin, nutritional ketosis is maintained without risk of ketoacidosis due to carefully regulated feedback control mechanisms and gradual adaptation [15].

Experimental and translational tools for ketone bodies

Ketone bodies for clinical or experimental purposes can be produced endogenously through a ketogenic diet or administered exogenously. The ketogenic diet involves limiting carbohydrate consumption, maintaining moderate protein intake, and meeting most of the body’s energy requirements with fat; this stimulates endogenous ketone production. Such diets have been used to treat intractable epilepsy and diabetes for over 100 years, and more recently have been investigated as treatments for type 2 diabetes and as co-therapies to treat various cancers [16,17,18]. A well-formulated ketogenic diet maintains blood BHB levels ~ 0.5–3 mM. However, the adoption of the ketogenic diet in both aging and military populations is not straightforward, not least because it necessitates dramatic changes to the habitual Western diet. Concerns for long-term use include possibly increasing the risk of cardiovascular disease in an at-risk aging population, or that ketoadaptation might impair physical performance [19, 20]. Although the impact of ketogenic diets on cardiovascular risk is controversial, ketogenic diets can beneficially modulate several risk factors for cardiovascular disease [21, 22]. Ketogenic diets have also been shown to be sustainable in elite athletes [23] and in military cadets [24] and produce changes in fat oxidation and body composition that may benefit performance.

An alternative approach to deliver the energetic and signaling effects of ketone bodies themselves, without the need for dietary modification, involves a class of compounds called “exogenous ketones” [25]. Exogenous ketone is a term widely used to describe the administration of ketone bodies or ketone body precursors. In reality, some forms of exogenous ketones leverage endogenous ketogenic pathways as well, but in a manner that avoids the usual suppression of ketogenesis by carbohydrate intake. During prolonged fasting or on a ketogenic diet, AcAc and BHB are produced endogenously in prodigious quantities—approximately 50 to 150 g/day [26], representing ~ 200–600 kcal of energy content. Thus, the key considerations for designing therapeutic exogenous ketones are to accommodate the food-like quantities that must be delivered, and to cope with the equimolar salt or acid load involved [25]. Existing categories of exogenous ketones include ketone salts, medium chain triglycerides, and ketone esters. An increasing number of exogenous ketone compounds are available and can be used alone or as an adjuvant to dietary methods; ketogenic diets prescribed for childhood epilepsies, for example, commonly include medium chain triglycerides to allow relatively more flexible carbohydrate intake [27].

Ketone salts are the salt form of beta-hydroxybutyrate, either as a sodium salt or with a mixture of cations. They are inexpensive to synthesize, are widely available to the public in consumer health products, and modestly increase blood BHB levels (~ 1 mM BHB increase) [25, 28]. Medium-chain fatty acids (unlike long-chain fatty acids) are not endogenously stored in appreciable amounts and their mitochondrial uptake and oxidation not inhibited by insulin. Medium-chain triglycerides (MCTs) are therefore a preferentially oxidized and ketogenic form of dietary fat that can provide a longer-lasting modest ketosis (~ 0.5–1 mM BHB increase) without added salt load [29]. MCTs have a body of clinical research supporting safety and efficacy for several metabolic outcomes in obese and diabetic patients, and early stage efficacy for improving metabolism in the aging brain and in Alzheimer’s disease [30,31,32,33]. Medium chain triglycerides are also widely commercially available, though acute dosing can be limited by gastrointestinal side effects [34] which appear to reduce with chronic administration [34,35,36,37]. Esters containing ketones and ketone precursors are also commercially available and result in higher blood BHB levels (~ 1–5 mM BHB increase) [28]. As there are several ketone bodies or ketone precursors, and the possibility of joining them in mono-, di-, or even tri-ester forms, the “ketone ester” family includes many possible compounds. Most recent clinical KE research has used a mono-ester of beta hydroxybutyrate and (R)-1,3 butanediol; however, other compounds are under development including a di-ester of acetoacetate and (R,S)-1,3 butanediol and a di-ester of hexanoic acid (a ketogenic medium chain fatty acid) and (R)-1,3 butanediol. The existing clinical literature on applications of ketone bodies includes studies using ketogenic diets and all of these varieties of exogenous ketones. Studies are underway of exogenous ketones in both diseases of aging and in military service members subjected to extreme environments.

Ketone body mechanisms relevant to resilience and rehabilitation

Emerging evidence shows that the ketone bodies BHB and AcAc are not only passive carriers of energy but also possess a variety of drug-like signaling functions that are hypothesized to directly and indirectly affect processes that become gradually dysregulated during aging or rapidly dysregulated as a result of trauma or stress in military service members. These include oxidative stress, inflammation, gene expression, lipid metabolism, and neuronal function [2]. These signaling activities are mediated by both covalent and non-covalent protein interactions. For example, BHB inhibits class I histone deacetylase (HDACs) enzymes, thereby regulating promoter histone acetylation and gene expression [38]. Beta-hydroxybutyrylation (BHBylation) is a novel covalent modification of the lysine tails of histone proteins, akin to acetylation, and its abundance on histones increases in response to exogenous BHB or in fasted mice [39]. These epigenetic effects result in up-regulation of the stress-response genes Nrf2, Foxo3, and Mt2, resulting in cytoprotection from oxidative stress in several model systems [40,41,42,43,44,45]. BHB directly interacts with the RNA binding protein hnRNPA1, thereby enhancing stabilization of the Yamanaka factor Oct4 mRNA, and leading to reduced senescence in mouse vascular endothelial cells [46]. BHB also binds to at least two cell-surface receptors, HCAR2 and FFAR3 (reviewed in [2]). HCAR2 activation on microglia is implicated in neuroprotection by ketogenic diet in a mouse stroke model; FFAR3 also has a role in dampening inflammatory activation in lung and bowel disease, and perhaps in other contexts as well [2].

AcAc possesses several signaling activities that are distinct from BHB. These include binding to GPR43 to modulate lipid metabolism [47] and activation of the MEK1-ERK1/2 cyclin D1 pathway to accelerate muscle cell proliferation and muscle regeneration [48]. AcAc also prominently inhibits the neuronal vesicular glutamate transporter VGLUT2, thereby inhibiting glutamate release from neurons [49]. Some protein binding activities are shared between AcAc and BHB, but at much different potency. For example, BHB is an ~ 10-fold more potent HDAC inhibitor than AcAc [38], while AcAc is a 10-fold more potent VGLUT2 inhibitor [49].

For some important signaling activities the specific protein interactions of BHB have not yet been fully defined. Perhaps most relevant to a resilience and rehabilitation context, BHB inhibits assembly and activation of the NLRP3 inflammasome through a yet unknown non-energy-dependent mechanism [50] in rodent models of inflammatory disease and in isolated human leukocytes [51], although clinical evidence remains mixed [52]. The NLRP3 inflammasome is a key mediator of innate immune inflammatory activation [53], both acutely and in chronic inflammation such as in gout [51] and T2DM [54]. Decreased activation of the NLRP3 inflammasome could partially explain the reduction in inflammatory markers in response to ketogenic diets in individuals with metabolic syndrome after 12 weeks [55].

The oxidation of ketone bodies generates changes in cellular metabolic biochemistry that can have fundamental indirect signaling effects, through altering the abundance of metabolites like acetyl-CoA and succinyl-CoA, and redistributing cellular NAD+/NADH and NADPi+/NADPH pools (reviewed in Newman and Verdin [2]). These effects will be context- and tissue-specific. AcAc and BHB are interconverted by an NAD-dependent enzyme (Bdh1), driven both by substrate concentration and by the mitochondrial NAD+/NADH ratio. Reduction of AcAc to BHB increases the NAD+/NADH ratio, promoting activation of other NAD-dependent enzymes with geroprotective properties such as the sirtuin deacylases [56, 57]. However, the resulting lower concentration of NADH impairs mitochondrial energy production [58]. Reduction of AcAc occurs in the liver during ketogenesis on a ketogenic diet, as well as potentially in peripheral tissues such as skeletal muscle that uptake AcAc and re-release as BHB [59]. On the other hand, oxidation of BHB to AcAc in peripheral tissues generates NADH, which is available for and increases the efficiency of ATP production but reduces the NAD+/NADH ratio. Importantly, in conditions of low intracellular glucose where the activity of the hexose monophosphate is compromised, ketones can provide an alternative route to maintain cytosolic reducing potential [58, 60] as set by the ratio of NADP+/NADPH. The metabolism of BHB in heart or brain leads to the formation of mitochondrial acetyl CoA and citrate [60, 61]. Mitochondrial citrate is transported to cytoplasm by the citrate–isocitrate carrier where its conversion to alpha-ketoglutarate leads to the regeneration of NADPH by the NADP-linked isocitrate dehydrogenase. Maintenance of cytosolic NADP/NADPH couple is an important mechanism by which ketones may be directly protective against cellular damage from acute and chronic oxidative stress (reviewed in [52, 58]).

Finally, ketone bodies and ketogenic diet can signal through multiple interactions with the microbiome that affect systemic function. BHB directly reduces the abundance of certain bacteria taxa including pro-inflammatory bifidiobacteria along with reducing intestinal pro-inflammatory Th17 cells in mice [62]. Reduced bifidiobacteria was also observed in a clinical study of modified Mediterranean ketogenic diet in older adults with or without cognitive impairment [63]; changes in the gut fungal mycobiome were also observed [64]. Changes in the gut microbiome on ketogenic diets also affect the levels of microbial-associated gamma-glutamylated metabolites that enter systemic circulation, resulting in an elevated brain GABA/glutamate ratio and suppression of epilepsy in mouse models [65].

Signaling and energetic properties of ketone bodies can integrate to generate higher-level changes in physiological function, most of which are only beginning to be mechanistically mapped. Although many of these effects are systemic, based on the hepatic production and systemic circulation of ketone bodies, new evidence is suggesting local physiological effects too, driven in some instances by extrahepatic ketogenesis. For example, hepatic production of AcAc is consumed locally by liver innate immune cells (Kuppfer cells), resulting in downstream metabolism of AcAc into the glycosaminoglycan pathway which regulates tissue fibrosis. Exogenous AcAc, but not BHB (Kuppfer cells lack expression of Bdh1), is protective against diet-induced liver fibrosis [66]. Overexpression of Bdh1 in the heart increases ketone body oxidation and similarly reduces fibrotic remodeling in a mouse heart failure model [67]. Interestingly, BHB may have the opposite effect on Kuppfer cell fibrotic phenotypes [66], demonstrating the importance of matching specific ketone bodies and activities, in this case, oxidation of AcAc, to specific clinical applications. Ketone body oxidation in lymphatic endothelial cells increased lymphangiogenesis, improves lymph vessel function, and reduces edema in mouse models of lymphedema [68]. A recent elegant study showed that local production of ketone bodies in Lgr5+ intestinal stem cells mediated their continued stemness via BHB inhibition of HDACs to reinforce Notch signaling [69]. This not only demonstrated a potentially general role for BHB in regulating stem cell function but also showed the relevance of local BHB production to clinically relevant phenotypes. Perhaps the clearest set of mechanistic studies of ketones in a specific disease state has shown that oxidation of BHB in cardiomyocytes to generate energy is an adaptive mechanism that supports cardiac function in preclinical heart failure models [70,71,72] and in small human physiology studies in healthy individuals and in heart failure patients [70, 73]. Acute intravenous infusion of BHB provides dose dependent (0.7–3.4 mM) hemodynamic and cardiac output improvement in both healthy humans and heart failure patients with reduced ejection fraction [74, 75]. The heart may be a site of local ketogenesis as well, as a component of this adaptation [76]. Similarly, brain uptake and oxidation of ketone bodies may mitigate the partial energy deficit that occurs in the aging or injured brain as a result of reduced glucose uptake and utilization; this defect is more pronounced in diseases of aging such as Alzheimer’s disease [30, 31], as well as traumatic brain injury [77].

Altogether, these biological activities of ketone bodies provide a number of mechanisms that may be relevant to resilience and rehabilitation contexts from bedside to battlefield. Ketone bodies promote stem cell function, promote blood and lymph vessel function, moderate acute and chronic inflammation, reduce tissue fibrosis, protect against oxidative and hypoxic stress, and provide resiliency against hypoglycemia and energetic stress (Fig. 1). These molecular mechanisms of ketone bodies have only been linked to specific diseases in a few cases such as heart failure, Alzheimer’s disease, and gout, and even then, largely through preclinical models. Clinical trials have yet to definitively demonstrate benefits of endogenous or exogenous ketosis in human diseases of aging or following military relevant acute stressors. A key research need is to provide clear mechanistic links in the most promising organ- and tissue-specific contexts to inform specific hypotheses and clinical study designs in promising applications such as traumatic brain injury or muscle rehabilitation.

Fig. 1
figure1

Mechanisms of ketone bodies relevant to resilience and rehabilitation

Brain: traumatic brain injury and cognitive resilience

A number of the biological mechanisms of ketone bodies may be relevant to resilience of the brain under acute or chronic stress. Long-term non-obese ketogenic diets in mice have been shown to extend healthy lifespan most prominently by protecting cognitive function in aging [78, 79]. The neuroprotective potential of ketone bodies in diverse neurological diseases has been extensively reviewed [80,81,82], including specifically for traumatic brain injury (TBI) [82,83,84,85]. Modulation of acute maladaptive inflammation via NLRP3 and HCAR2, cytoprotection against oxidative stress, induction of resilience genes, and maintenance of cellular ATP via ketone oxidation might all play a role in resilience to TBI. These different mechanisms may operate in specific cell types (e.g., protection against neuronal death vs. inhibition of microglial activation) and at different times (e.g., reduced energetic stress during acute injury vs. reduced chronic maladaptive inflammation). In multiple, diverse rodent models of TBI, both prophylactic and post-injury ketogenic diet and exogenous ketone administration reduce cerebral edema, reduce apoptosis, improves cerebral metabolism, and improve long-term behavioral outcomes [85, 86].

Clinical studies of ketogenic diets or exogenous ketones related to the brain have mostly focused on resilience to or compensation for neurodegenerative disease of aging such as Alzheimer’s disease (AD). Small studies of medium chain triglycerides and ketogenic diets have demonstrated favorable effects on brain energetics, AD biomarkers, cerebral perfusion, and/or cognitive improvement [30, 31, 87]. A recent systematic review summarized 10 randomized controlled trials, which although highly heterogeneous in design and outcomes and clearly representing an early stage of research, show promise overall for AD [88]. A few small clinical studies specifically of ketones in military relevant settings such as TBI are now underway, largely at the safety/feasibility stage. Examples include an RCT of adolescents given ketone ester post-concussion at University of Alabama (NCT04079907), pilot studies of a ketogenic diet for patients with severe TBI in neurocritical care at University of Missouri (NCT03982602) and University of Copenhagen (NCT04308577), and a pilot study of MCTs for patients with severe TBI or subarachnoid hemorrhage in Switzerland (NCT02716532). Exogenous ketones are also being studied for their potential to mitigate hypoxia induced decrements in cognitive performance in pilots (NCT03659825).

Muscle: anticatabolic, synthetic, and regenerative effects

An emerging potential application of ketogenic diet and ketone bodies is protecting against muscle loss in settings of starvation [13, 89], atrophy [90, 91], cachexia [91,92,93], or sarcopenia [78], as well as augmentation of muscle protein synthesis [94, 95] and damage-induced muscular regeneration [48]. The importance of this use case cannot be overstated for both the aging population, who rapidly lose muscle mass and function as a result of immobility [96], and the military population, who are at increased risk of muscle degradation or injury during training and combat [97, 98]. The “anti-catabolic” effect of ketone bodies is grounded in modulation of inflammation and cellular biochemistry and is consistent with the hypothesized evolutionary role of ketogenesis in sparing muscle catabolism during starvation by providing an alternative to gluconeogenesis for systemic energy supply [13, 89, 99]. Ketogenic diet used for weight loss in obese young military personnel causes loss of fat mass without significant changes in lean body mass or a military-specific set of physical performance tasks [24]. Both ketogenic diet and ketone body infusion reduce leucine oxidation, nitrogen excretion and alanine muscle efflux, and markers of protein catabolism, during starvation or an acute inflammatory insult [13, 89, 100,101,102,103,104]. Interestingly, ketone bodies were shown to have favorable effect on muscle protein turnover compared with glucose-induced hyper-insulinemia with LPS infusion [104], suggesting substitution of insulinogenic substrate for ketones may influence skeletal muscle anabolism in inflammatory environments. Altogether, exogenous ketones and ketogenic diet have been shown to reduce muscle wasting in a variety of cancer cachexia and inflammation-induced atrophy environments [91,92,93, 104,105,106].

In addition to reducing catabolism, there is some evidence that ketogenic diets or ketone bodies may promote protein synthesis in muscle via activation of the mTORC1 pathway. The interaction of ketogenic diet or ketone bodies with TOR is a complex topic that requires further detailed mechanistic investigation. In clinical studies, exogenous ketone bodies augment leucine-induced skeletal muscle protein synthesis [94, 95] via activation of the mTORC1 pathway [95]. Similarly, a lifespan study of ketogenic diet in mice showed attenuation of age-related muscle loss and preservation of muscle strength that were associated with markers of increased mTORC1 activation in skeletal muscle [78]. However, the effect of ketogenic diet or ketone bodies on TOR activity appears to be highly context- and/or tissue-dependent. The same mouse lifespan study found reduced TOR activity in the liver [78], and a second mouse lifespan study of ketogenic diet showed gene expression patterns consistent with reduced TOR activity in both liver and kidney [79]. In the diabetic kidney, ketone bodies are reported to inhibit aberrantly elevated mTORC1 signaling [107]. Finally, mTORC1 activity must be suppressed in the liver to permit hepatic ketogenesis during fasting [108]. The specific mechanisms by which ketone bodies interact with TOR pathway components remain to be elucidated.

These anticatabolic effects across dietary restricted inflammatory, sarcopenic, and cachexic environments, a protein synthetic role augmenting leucine-induced mTORC1 activation, and muscle cell proliferation and satellite cell regenerative effects in muscle hold clinical relevance across age-related diseases as well as muscle resilience, rehabilitation, and recovery. The molecular pathways thought to regulate these processes are multifaceted and include NLRP3, HCAR2, NFκB, HDACs, ubiquitination, mTORC1, MEK/ERK, and/or cellular NADPH pools [48, 58, 90, 91, 94, 95]. Early clinical trials at University of Bath (NCT03574987) and University of Rome (NCT04019431) are investigating body composition changes on low carbohydrate/ketogenic diets. Further clinical investigation of exogenous and endogenous ketones in the context of skeletal muscle anticatabolic, synthesis, and regeneration is needed and may prove fruitful for both aging and for operational muscle rehabilitation and resilience.

Key gaps and limitations in current knowledge

The translation of ketone body biology from the bench to bedside and battlefield is still in the early stages. This translational science builds upon extensive and growing clinical experience, going back decades, with the use of ketogenic diets to treat epilepsy, childhood genetic disorders, and obesity and T2DM. Ketogenic diets are safe, accessible, and potently therapeutic but have inherent limitations as clinical interventions, including the complexity and feasibility of large-scale dietary changes, and the pleotropic effects that may or may not focus on key mechanisms for a specific condition. Recently, tools have emerged to provide ketone bodies more directly in the form of exogenous ketones: ketone salts, medium-chain triglycerides, and ketone esters. These too have limitations in palatability, cost, and the need for data on long-term use in both healthy young and aging populations. The pleotropic nature of ketogenic diet and exogenous ketones requires appropriate caution in designing clinical trials. Inhibiting acute inflammatory activation, increasing vasodilation, changes in blood chemistry, etc., may be helpful in some contexts but harmful in others (reviewed for the context of severe respiratory infection in [52]). Additional caution is warranted for patients or conditions where normal metabolic regulatory control is disrupted, to avoid harmful ketoacidosis.

The key scientific gap is to understand the particular molecular mechanisms that are most important for the application of ketone bodies in a specific clinical context (Table 1). This knowledge can then inform the choice and optimization of therapeutic interventions. For example, the body adapts in a comprehensive and coordinated manner to prolonged fasting or ketogenic diet, including increasing the efficiency of transport and utilization of fatty acids and ketone bodies for energy, especially in the brain. This adaptation may be helpful and would be encouraged in use cases that require oxidation of ketone bodies for energy, but counterproductive if the use case depends on drug-like direct protein binding activities and higher circulating levels of ketone bodies. It seems likely that adaptation is not required for many applications of exogenous ketosis; however, it is not clear if this applies in all situations. The efficacious dose, duration, timing, and pharmacokinetics of ketogenic therapy have not been clearly defined for most potential clinical interventions. For example, in the context of TBI would ketone bodies be most useful at improving pre-exposure resilience, mitigating injury during the exposure, or improving recovery after the exposure? Even how to define a “therapeutic level” of blood ketones is a unique question for a molecule whose primary route of clearance may be identical in some cases to its therapeutic action (oxidation to generate ATP). Ratios of the physiological ketone bodies, BHB and AcAc, can be manipulated by the choice of exogenous ketone compound, which could have implications for the energetic, signaling, and redox effects of each intervention. As ketone bodies both modulate and are dependent on whole-body metabolic function, there may be important interactions with diet and other factors such as age and metabolic health [109,110,111]. An understanding of key condition-specific mechanisms permits the selection or novel design of exogenous ketones to optimize each mechanism, perhaps in concert with adjuvant interventions to bolster other relevant downstream molecular pathways. In general, the tools and concepts already exist to proceed with informative proof of concept studies of ketogenic diet or exogenous ketones, but these questions will need to be worked out for individual clinical and field applications to optimize their therapeutic potential.

Table 1 Key research needs

Summary

The pleotropic molecular effects of ketone bodies on mechanisms related to aging are an important emerging field with strong overlap with pathways implicated in military-relevant resilience and rehabilitation. Key molecular mechanisms include energetic support, attenuation of inflammation and oxidative stress, and effects on tissue fibrosis, stem cell function, and vascular function. While translation of the benefits of ketones in many of the hypothesized clinical and operational settings has yet to be validated, some areas have growing preclinical support. Areas that are particularly advanced include the use of ketone bodies in animal models of brain resilience and TBI, and muscle wasting/atrophy and damage across stressful environments. The tools and concepts exist to carry out early stage clinical investigations of ketogenic diet and exogenous ketones in these areas, and some clinical studies are already underway, but considerable work is needed to elucidate therapeutic effects. Preclinical models offer the best opportunity to rapidly study the mechanisms of action of ketone bodies across multiple applications, and speed the progress to well-designed clinical trials. Overall, ketogenic diet and exogenous ketones represent a rapidly translatable set of interventions with strong biological plausibility and some clinical proof of concept data to support investigation in both aging and military-relevant resilience and rehabilitation contexts particularly involving cognitive resilience, traumatic brain injury, and maintenance and recovery of muscle function through serious damage and/or illness.

Abbreviations

AcAc:

Acetoacetate

BHB:

Beta-hydroxybutyrate (aka 3-hydroxybutyrate)

MCTs:

Medium chain triglycerides

NLRP3:

NOD-, LRR- and pyrin domain-containing protein 3

T2DM:

Type 2 diabetes mellitus

TBI:

Traumatic brain injury

References

  1. 1.

    Veech RL, Bradshaw PC, Clarke K, Curtis W, Pawlosky R, King MT. Ketone bodies mimic the life span extending properties of caloric restriction. IUBMB Life. 2017;69(5):305–14.

    CAS  PubMed  Google Scholar 

  2. 2.

    Newman JC, Verdin E. beta-Hydroxybutyrate: a signaling metabolite. Annu Rev Nutr. 2017;37:51–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Han YM, Ramprasath T, Zou MH. β-Hydroxybutyrate and its metabolic effects on age-associated pathology. Exp Mol Med. 2020;52(4):548–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Mattson MP, Moehl K, Ghena N, Schmaedick M, Cheng A. Intermittent metabolic switching, neuroplasticity and brain health. Nat Rev Neurosci. 2018;19(2):63–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Miller MW, Sadeh N. Traumatic stress, oxidative stress and post-traumatic stress disorder: neurodegeneration and the accelerated-aging hypothesis. Mol Psychiatry. 2014;19(11):1156–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Tamman AJF, Montalvo-Ortiz JL, Southwick SM, Krystal JH, Levy BR, Pietrzak RH. Accelerated DNA methylation aging in U.S. military veterans: results from the National Health and Resilience in Veterans Study. Am J Geriatr Psychiatry. 2019;27(5):528–32.

    PubMed  Google Scholar 

  7. 7.

    Veitch DP, Friedl KE, Weiner MW. Military risk factors for cognitive decline, dementia and Alzheimer's disease. Curr Alzheimer Res. 2013;10(9):907–30.

    CAS  PubMed  Google Scholar 

  8. 8.

    Songer TJ, LaPorte RE. Disabilities due to injury in the military. Am J Prev Med. 2000;18(3 Suppl):33–40.

    CAS  PubMed  Google Scholar 

  9. 9.

    Feuerstein M, Berkowitz SM, Peck CA Jr. Musculoskeletal-related disability in US Army personnel: prevalence, gender, and military occupational specialties. J Occup Environ Med. 1997;39(1):68–78.

    CAS  PubMed  Google Scholar 

  10. 10.

    Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev. 2012;36(5):1376–81.

    PubMed  Google Scholar 

  11. 11.

    Robinson AM, Williamson DH. Physiological roles of ketone-bodies as substrates and signals in mammalian-tissues. Physiol Rev. 1980;60(1):143–87.

    CAS  PubMed  Google Scholar 

  12. 12.

    Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15(6):412–26.

    CAS  PubMed  Google Scholar 

  13. 13.

    Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1–22.

    CAS  PubMed  Google Scholar 

  14. 14.

    Rich AJ. Ketone bodies as substrates. Proc Nutr Soc. 1990;49(3):361–73.

    CAS  PubMed  Google Scholar 

  15. 15.

    Krebs HA. The regulation of the release of ketone bodies by the liver. Adv Enzym Regul. 1966;4:339–54.

    CAS  Google Scholar 

  16. 16.

    Wheless, J.W., Chapter 2—History and origin of the ketogenic diet. Epilepsy and the ketogenic diet. 2004: Humana Press Inc.

  17. 17.

    Branco AF, Ferreira A, Simões RF, Magalhães-Novais S, Zehowski C, Cope E, et al. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Investig. 2016;46(3):285–98.

    Google Scholar 

  18. 18.

    Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer—where do we stand? Mol Metab. 2020;33:102–21.

    CAS  PubMed  Google Scholar 

  19. 19.

    Burke LM. Re-examining high-fat diets for sports performance: did we call the “Nail in the Coffin” too soon? Sports Med. 2015;45(Suppl 1):S33–49.

    PubMed  Google Scholar 

  20. 20.

    Burke L and Kiens B., “fat adaptations” for athletic performance: the nail in the coffin? J Appl Physiol, 2006. 100.

  21. 21.

    Athinarayanan SJ, et al., Long-term effects of a novel continuous remote care intervention including nutritional ketosis for the management of type 2 diabetes: a 2-year non-randomized clinical trial. Front Endocrinol, 2019. 10(348).

  22. 22.

    Diamond DM, O'Neill BJ, Volek JS. Low carbohydrate diet: are concerns with saturated fat, lipids, and cardiovascular disease risk justified? Curr Opin Endocrinol Diabetes Obes. 2020;27(5):291–300.

    CAS  PubMed  Google Scholar 

  23. 23.

    Volek JS, Freidenreich DJ, Saenz C, Kunces LJ, Creighton BC, Bartley JM, et al. Metabolic characteristics of keto-adapted ultra-endurance runners. Metabolism. 2016;65(3):100–10.

    CAS  PubMed  Google Scholar 

  24. 24.

    LaFountain RA, Miller VJ, Barnhart EC, Hyde PN, Crabtree CD, McSwiney FT, et al. Extended ketogenic diet and physical training intervention in military personnel. Mil Med. 2019;184(9–10):e538–47.

    PubMed  Google Scholar 

  25. 25.

    Poff AM, Koutnik AP, Egan B. Nutritional ketosis with ketogenic diets or exogenous ketones: features, convergence, and divergence. Curr Sports Med Rep. 2020;19(7):251–9.

    PubMed  Google Scholar 

  26. 26.

    Cahill G, Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc. 2003;114(0065–7778 (Print)):149–61 discussion 162-3.

    PubMed  PubMed Central  Google Scholar 

  27. 27.

    Gavrilovici C and Rho JM, Metabolic epilepsies amenable to ketogenic therapies: indications, Contra-indications and underlying mechanisms. J Inherit Metab Dis, 2020.

  28. 28.

    Stubbs B, et al., On the metabolism of exogenous ketones in humans. Front Physiol 2017.

  29. 29.

    Vandenberghe, C., et al., Tricaprylin alone increases plasma ketone response more than coconut oil or other medium-chain triglycerides: an acute crossover study in healthy adults. Curr Dev Nutr, 2017. 1(4).

  30. 30.

    Croteau E, Castellano CA, Richard MA, Fortier M, Nugent S, Lepage M, et al. Ketogenic medium chain triglycerides increase brain energy metabolism in Alzheimer's disease. J Alzheimers Dis. 2018;64(2):551–61.

    CAS  PubMed  Google Scholar 

  31. 31.

    Fortier M, Castellano CA, Croteau E, Langlois F, Bocti C, St-Pierre V, et al. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 2019;15(5):625–34.

    PubMed  Google Scholar 

  32. 32.

    Eckel RH, Hanson AS, Chen AY, Berman JN, Yost TJ, Brass EP. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects. Diabetes. 1992;41(5):641–7.

    CAS  PubMed  Google Scholar 

  33. 33.

    Clegg ME. Medium-chain triglycerides are advantageous in promoting weight loss although not beneficial to exercise performance. Int J Food Sci Nutr. 2010;61(7):653–79.

    CAS  PubMed  Google Scholar 

  34. 34.

    Ööpik V, Timpmann S, Medijainen L, Lemberg H. Effects of daily medium-chain triglyceride ingestion on energy metabolism and endurance performance capacity in well-trained runners. Nutr Res. 2001;21(8):1125–35.

    Google Scholar 

  35. 35.

    Thomas DD, Stockman MC, Yu L, Meshulam T, McCarthy AC, Ionson A, et al. Effects of medium chain triglycerides supplementation on insulin sensitivity and beta cell function: a feasibility study. PLoS One. 2019;14(12):e0226200.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Misell, L.M., et al., Chronic medium-chain trilgycerol onsumption and endurance performance in trained runners. J Sports Med Phys Fitness, 2001. 41(2).

  37. 37.

    Thorburn MS, et al. Attenuated gastric distress but no benefit to performance with adaptation to octanoate-rich esterified oils in well-trained male cyclists. J Appl Physiol (1985). 2006;101(6):1733–43.

    CAS  Google Scholar 

  38. 38.

    Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, le Moan N, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339(6116):211–4.

    CAS  PubMed  Google Scholar 

  39. 39.

    Xie Z, Zhang D, Chung D, Tang Z, Huang H, Dai L, et al. Metabolic regulation of gene expression by histone lysine beta-hydroxybutyrylation. Mol Cell. 2016;62(2):194–206.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Wei T, Tian W, Liu F, Xie G. Protective effects of exogenous β-hydroxybutyrate on paraquat toxicity in rat kidney. Biochem Biophys Res Commun. 2014;447(4):666–71.

    CAS  PubMed  Google Scholar 

  41. 41.

    Izuta Y, Imada T, Hisamura R, Oonishi E, Nakamura S, Inagaki E, et al. Ketone body 3-hydroxybutyrate mimics calorie restriction via the Nrf2 activator, fumarate, in the retina. Aging Cell. 2018;17(1):e12699.

    Google Scholar 

  42. 42.

    Meroni E, et al., Metabolic responses in endothelial cells following exposure to ketone bodies. Nutrients, 2018. 10(2).

  43. 43.

    Kim DY, Davis LM, Sullivan PG, Maalouf M, Simeone TA, Brederode J, et al. Ketone bodies are protective against oxidative stress in neocortical neurons. J Neurochem. 2007;101(5):1316–26.

    CAS  PubMed  Google Scholar 

  44. 44.

    Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, le Moan N, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339(6116):211–4.

    CAS  PubMed  Google Scholar 

  45. 45.

    Kong G, Huang Z, Ji W, Wang X, Liu J, Wu X, et al. The ketone metabolite β-Hydroxybutyrate attenuates oxidative stress in spinal cord injury by suppression of class I histone deacetylases. J Neurotrauma. 2017;34(18):2645–55.

    PubMed  Google Scholar 

  46. 46.

    Han Y-M, et al. β-Hydroxybutyrate prevents vascular senescence through hnRNP A1-mediated upregulation of Oct4. Mol Cell. 2018;71(6):1064–1078.e5.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Miyamoto J, Ohue-Kitano R, Mukouyama H, Nishida A, Watanabe K, Igarashi M, et al. Ketone body receptor GPR43 regulates lipid metabolism under ketogenic conditions. Proc Natl Acad Sci. 2019;116(47):23813–21.

    CAS  PubMed  Google Scholar 

  48. 48.

    Zou X, Meng J, Li L, Han W, Li C, Zhong R, et al. Acetoacetate accelerates muscle regeneration and ameliorates muscular dystrophy in mice. J Biol Chem. 2016;291(5):2181–95.

    CAS  PubMed  Google Scholar 

  49. 49.

    Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, et al. Metabolic control of vesicular glutamate transport and release. Neuron. 2010;68(1):99–112.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Goldberg EL, Asher JL, Molony RD, Shaw AC, Zeiss CJ, Wang C, et al. Beta-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. 2017;18(9):2077–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Stubbs, B.J., et al., Investigating ketone bodies as immunometabolic countermeasures against respiratory viral infections. Medicine

  53. 53.

    Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–89.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Sepehri Z, Kiani Z, Afshari M, Kohan F, Dalvand A, Ghavami S. Inflammasomes and type 2 diabetes: an updated systematic review. Immunol Lett. 2017;192:97–103.

    CAS  PubMed  Google Scholar 

  55. 55.

    Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, Bibus DM, et al. Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids. 2008;43(1):65–77.

    CAS  PubMed  Google Scholar 

  56. 56.

    Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, et al. The NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154(2):430–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Veech RL, Todd King M, Pawlosky R, Kashiwaya Y, Bradshaw PC, Curtis W. The “great” controlling nucleotide coenzymes. IUBMB Life. 2019;71(5):565–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Elia M, Wood S, Khan K, Pullicino E. Ketone body metabolism in lean male adults during short-term starvation, with particular reference to forearm muscle metabolism. Clin Sci (Lond). 1990;78(6):579–84.

    CAS  Google Scholar 

  60. 60.

    Kashiwaya Y, King MT, Veech RL. Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart. Am J Cardiol. 1997;80(3a):50a–64a.

    CAS  PubMed  Google Scholar 

  61. 61.

    Pawlosky RJ, Kemper MF, Kashiwaya Y, King MT, Mattson MP, Veech RL. Effects of a dietary ketone ester on hippocampal glycolytic and tricarboxylic acid cycle intermediates and amino acids in a 3xTgAD mouse model of Alzheimer's disease. J Neurochem. 2017;141(2):195–207.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Ang QY, et al. Ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells. Cell. 2020;181(6):1263–1275.e16.

    CAS  PubMed  Google Scholar 

  63. 63.

    Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–42.

    PubMed  PubMed Central  Google Scholar 

  64. 64.

    Nagpal R, Neth BJ, Wang S, Mishra SP, Craft S, Yadav H. Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's disease markers in subjects with mild cognitive impairment: a pilot study. EBioMedicine. 2020;59:102950.

    PubMed  PubMed Central  Google Scholar 

  65. 65.

    Olson CA, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018;173(7):1728–1741.e13.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Puchalska P, et al. Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis. Cell Metab. 2019;29(2):383–398.e7.

    CAS  PubMed  Google Scholar 

  67. 67.

    Uchihashi, M., et al., Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure. Circ Heart Fail, 2017. 10(12).

  68. 68.

    García-Caballero M, Zecchin A, Souffreau J, Truong ACK, Teuwen LA, Vermaelen W, et al. Role and therapeutic potential of dietary ketone bodies in lymph vessel growth. Nat Metab. 2019;1(7):666–75.

    PubMed  Google Scholar 

  69. 69.

    Cheng CW, et al. Ketone body signaling mediates intestinal stem cell homeostasis and adaptation to diet. Cell. 2019;178(5):1115–1131.e15.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI insight. 2019;4(4):e124079.

    PubMed Central  Google Scholar 

  71. 71.

    Byrne Nikole J, et al. Chronically elevating circulating ketones can reduce cardiac inflammation and blunt the development of heart failure. Circ Heart Fail. 2020;13(6):e006573.

    CAS  PubMed  Google Scholar 

  72. 72.

    Uchihashi M, et al. Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload–induced heart failure. Circ Heart Fail. 2017;10(12):e004417.

    CAS  PubMed  Google Scholar 

  73. 73.

    Selvaraj S, Kelly DP, Margulies KB. Implications of altered ketone metabolism and therapeutic ketosis in heart failure. Circulation. 2020;141(22):1800–12.

    PubMed  PubMed Central  Google Scholar 

  74. 74.

    Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139(18):2129–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Gormsen LC, et al., Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc, 2017. 6(3).

  76. 76.

    Song JP, et al., Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy. Sci Transl Med, 2020. 12(530).

  77. 77.

    Yoshino A, Hovda DA, Kawamata T, Katayama Y, Becker DP. Dynamic changes in local cerebral glucose utilization following cerebral concussion in rats: evidence of a hyper- and subsequent hypometabolic state. Brain Res. 1991;561(1):106–19.

    CAS  PubMed  Google Scholar 

  78. 78.

    Roberts MN, et al. A ketogenic diet extends longevity and healthspan in adult mice. Cell Metab. 2017;26(3):539–546.e5.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Newman JC, et al. Ketogenic diet reduces midlife mortality and improves memory in aging mice. Cell Metab. 2017;26(3):547–557.e8.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. 80.

    Wood TR, Stubbs BJ, Juul SE. Exogenous ketone bodies as promising neuroprotective agents for developmental brain injury. Dev Neurosci. 2018;40(5–6):451–62.

    CAS  PubMed  Google Scholar 

  81. 81.

    Gano LB, Patel M, Rho JM. Ketogenic diets, mitochondria, and neurological diseases. J Lipid Res. 2014;55(11):2211–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. 82.

    Yang H, Shan W, Zhu F, Wu J, Wang Q. Ketone bodies in neurological diseases: focus on neuroprotection and underlying mechanisms. Front Neurol. 2019;10:585.

    PubMed  PubMed Central  Google Scholar 

  83. 83.

    Prins ML, Matsumoto JH. The collective therapeutic potential of cerebral ketone metabolism in traumatic brain injury. J Lipid Res. 2014;55(12):2450–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Arora N, Mehta TR. Role of the ketogenic diet in acute neurological diseases. Clin Neurol Neurosurg. 2020;192:105727.

    PubMed  Google Scholar 

  85. 85.

    McDougall A, Bayley M, Munce SE. The ketogenic diet as a treatment for traumatic brain injury: a scoping review. Brain Inj. 2018;32(4):416–22.

    PubMed  Google Scholar 

  86. 86.

    Prins ML. Cerebral metabolic adaptation and ketone metabolism after brain injury. J Cereb Blood Flow Metab : official journal of the International Society of Cerebral Blood Flow and Metabolism. 2008;28(1):1–16.

    CAS  Google Scholar 

  87. 87.

    Neth BJ, Mintz A, Whitlow C, Jung Y, Solingapuram Sai K, Register TC, et al. Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. Neurobiol Aging. 2020;86:54–63.

    CAS  PubMed  Google Scholar 

  88. 88.

    Grammatikopoulou MG, et al., To keto or not to keto? A systematic review of randomized controlled trials assessing the effects of ketogenic therapy on Alzheimer disease. Adv Nutr, 2020.

  89. 89.

    Felig P, Owen OE, Wahren J, Cahill GF Jr. Amino acid metabolism during prolonged starvation. J Clin Invest. 1969;48(3):584–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. 90.

    Koutnik AP, D'Agostino DP, Egan B. Anticatabolic effects of ketone bodies in skeletal muscle. Trends Endocrinol Metab. 2019;30(4):227–9.

    CAS  PubMed  Google Scholar 

  91. 91.

    Koutnik AP, et al., Ketone bodies attenuate wasting in models of atrophy. J Cachexia Sarcopenia Muscle 2020

  92. 92.

    Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2:18.

    PubMed  PubMed Central  Google Scholar 

  93. 93.

    Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr. 1988;47(1):42–8.

    CAS  PubMed  Google Scholar 

  94. 94.

    Nair KS, Welle SL, Halliday D, Campbell RG. Effect of beta-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans. J Clin Invest. 1988;82(1):198–205.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. 95.

    Vandoorne T, de Smet S, Ramaekers M, van Thienen R, de Bock K, Clarke K, et al. Intake of a ketone ester drink during recovery from exercise promotes mTORC1 signaling but not glycogen resynthesis in human muscle. Front Physiol. 2017;8:310.

    PubMed  PubMed Central  Google Scholar 

  96. 96.

    Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability: “she was probably able to ambulate, but I’m not sure.”. Jama. 2011;306(16):1782–93.

    CAS  PubMed  Google Scholar 

  97. 97.

    Church, D.D., et al., Mitigation of muscle loss in stressed physiology: military relevance. Nutrients, 2019. 11(8).

  98. 98.

    Corona BT, Rivera JC, Owens JG, Wenke JC, Rathbone CR. Volumetric muscle loss leads to permanent disability following extremity trauma. J Rehabil Res Dev. 2015;52(7):785–92.

    PubMed  Google Scholar 

  99. 99.

    Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr. Brain metabolism during fasting. J Clin Invest. 1967;46(10):1589–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. 100.

    Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and kidney metabolism during prolonged starvation. J Clin Invest. 1969;48(3):574–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. 101.

    Sherwin RS, Hendler RG, Felig P. Effect of ketone infusions on amino acid and nitrogen metabolism in man. J Clin Invest. 1975;55(6):1382–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  102. 102.

    Maiz A, Moldawer LL, Bistrian BR, Birkhahn RH, Long CL, Blackburn GL. Monoacetoacetin and protein metabolism during parenteral nutrition in burned rats. Biochem J. 1985;226(1):43–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  103. 103.

    Phinney S, et al. The human metabolic response to chronic ketosis without caloric restriction: preservation of submaximal exercise capability with reduced carbohydrate oxidation. Metabolism. 1983;32(8):769–76.

    CAS  PubMed  Google Scholar 

  104. 104.

    Thomsen HH, Rittig N, Johannsen M, Møller AB, Jørgensen JO, Jessen N, et al. Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies. Am J Clin Nutr. 2018;108(4):857–67.

    PubMed  Google Scholar 

  105. 105.

    Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer. 1987;56(1):39–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. 106.

    Nakamura, K., et al., A Ketogenic formula prevents tumor progression and cancer cachexia by attenuating systemic inflammation in colon 26 tumor-bearing mice. Nutrients, 2018. 10(2).

  107. 107.

    Tomita I, Kume S, Sugahara S, Osawa N, Yamahara K, Yasuda-Yamahara M, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32:404–419.e6.

    CAS  PubMed  Google Scholar 

  108. 108.

    Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature. 2010;468(7327):1100–4.

    CAS  PubMed  Google Scholar 

  109. 109.

    Balasse EO, Fery F. Ketone-body production and disposal—effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989;5(3):247–70.

    CAS  PubMed  Google Scholar 

  110. 110.

    Fery F, Balasse EO. Ketone-body production and disposal in diabetic ketosis—a comparison with fasting ketosis. Diabetes. 1985;34(4):326–32.

    CAS  PubMed  Google Scholar 

  111. 111.

    Kackley ML, Short JA, Hyde PN, LaFountain RA, Buga A, Miller VJ, et al. A pre-workout supplement of ketone salts, caffeine, and amino acids improves high-intensity exercise performance in keto-naïve and keto-adapted individuals. J Am Coll Nutr. 2020;39(4):290–300.

    CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Institutes of Health K08 AG048354 and R01 AG067333 (J.C.N.) and Buck Institute institutional funds (J.C.N and B.J.S.).

Author information

Affiliations

Authors

Contributions

J.C.N., B.J.S, and A.P.K. wrote the manuscript and provided critical editing. J.S.V. provided additional revised text and critical editing. J.C.N. conceptualized the manuscript, provided the figure and table, and supervised writing and editing.

Corresponding author

Correspondence to John C. Newman.

Ethics declarations

Competing interests

J.C.N. is a co-founder of and shareholder in BHB Therapeutics LTD., which is developing products relating to ketone bodies, and is on the scientific advisory board of Virta Health, Inc. B.J.S. is a shareholder of HVMN Inc., which markets products relating to ketone bodies and of BHB Therapeutics Ltd. J.C.N., B.J.S, and A.P.K are inventors on patents related to the use of ketone bodies. J.S.V. receives royalties for low-carbohydrate nutrition books; is founder, consultant, and stockholder of Virta Health, Inc. and is a member of the advisory boards for Atkins Nutritionals Inc., UCAN Co., and Ketone Sciences.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Stubbs, B.J., Koutnik, A.P., Volek, J.S. et al. From bedside to battlefield: intersection of ketone body mechanisms in geroscience with military resilience. GeroScience 43, 1071–1081 (2021). https://doi.org/10.1007/s11357-020-00277-y

Download citation

Keywords

  • Metabolism
  • Ketone bodies
  • Aging
  • Geroscience
  • TBI
  • Sarcopenia